| CEDARS-SINAI MEDICAL CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20120088730 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE - The present invention relates to the discovery that the two ACE domains can have very different effects on cytokine expression. In one embodiment, the present invention provides a method of regulating and/or treating a condition in a subject by administering a therapeutically effective dosage of site specific ACE inhibitor. In another embodiment, the condition is inflammation and/or immune response. | 04-12-2012 |
| 20120088245 | METHODS OF DIAGNOSING INSULIN RESISTANCE AND SENSITIVITY - Methods of diagnosing susceptibility to metabolic insulin resistance and other related conditions are disclosed. The method provides means of diagnosing susceptibility to insulin resistance in Hispanic Americans by determining the presence of a risk haplotype at the LPL locus, the LPIN1 locus, and/or elevated levels of gamma-glutamyl transferase. | 04-12-2012 |
| 20120079611 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY - This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBM such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis. | 03-29-2012 |
| 20120073585 | METHODS OF PREDICTING COMPLICATION AND SURGERY IN CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors. | 03-29-2012 |
| 20120070899 | EFFECTIVE VECTOR PLATFORM FOR GENE TRANSFER AND GENE THERAPY - The invention relates to the discovery that mutations of serine residues of an AAV capsid results in significantly greater transfection efficiency than the wild type AAV2 virus. In one embodiment, the present invention provides a method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein, where the inhibition of the phosphorylation of one or more serine residues results in a decrease of ubiquitination of the virus capsid protein in the cell. In another embodiment, one of the one or more serine residues is Serine 264. In another embodiment, the Serine 264 residue is mutated to Alanine (S 264 A). | 03-22-2012 |
| 20120041082 | METHODS OF USING SMAD3 AND JAK2 GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2 loci. | 02-16-2012 |
| 20120004181 | TARGETED DELIVERY SYSTEM - The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle. | 01-05-2012 |
| 20110305704 | ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI - Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described. | 12-15-2011 |
| 20110300112 | METHODS FOR ENHANCING YIELD OF STEM CELL CULTURES AND ENHANCING STEM CELL THERAPY - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies. | 12-08-2011 |
| 20110300111 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS - Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration peptide so that a reprogrammed mammalian cell that exhibits at least one characteristic of pluripotency is generated. Also presented herein are methods for cardiac differentiation of a mammalian cell without the use of viral or plasmid vectors. In one aspect, such methods involve contacting a mammalian cell exhibiting at least one characteristic of pluripotency with a transducible polypeptide, so that cardiac differentiation of the cell occurs. | 12-08-2011 |
| 20110294726 | ANTIBIOTIC THERAPY TO REDUCE THE LIKELIHOOD OF DEVELOPING POST-INFECTIOUS IRRITABLE BOWEL SYNDROME - The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term irregular bowel pattern and reducing the likelihood of developing non-ulcer dyspepsia. The methods comprise providing an antibiotic and administering the antibiotic to a subject in need thereof. | 12-01-2011 |
| 20110286932 | OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE - The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively. | 11-24-2011 |
| 20110280834 | METHODS AND COMPOSITIONS FOR CARDIAC TISSUE REGENERATION - Methods for treating an injured cardiac tissue in a subject are provided herein. Methods for improving survival, engraftment and proliferation of stem cells in a cardiac tissue are provided. Also provided are methods for generating cardiac cells. Further provided are compositions for generating cardiac cells in a subject. | 11-17-2011 |
| 20110274708 | SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING - The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions. | 11-10-2011 |
| 20110269230 | METHODS AND COMPOSITIONS FOR MAINTAINING GENOMIC STABILITY IN CULTURED STEM CELLS - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies. | 11-03-2011 |
| 20110257458 | METHOD OF USING TUMOR CELL DEBRIS TO REDUCE BRAIN TUMOR RECURRENCE OR GROWTH - The present invention describes compositions comprising tumor cell debris, tumor lysate or tumor antigens and methods of using tumor cell debris, tumor lysate or tumor antigens for stimulating a specific immune response. The compositions may further comprise at least one TLR ligand. The stimulation of the specific immune response may be used to treat tumors, particularly, brain tumors. The treatment method may also reduce the recurrence of a tumor and/or inhibit or slow down the growth of a tumor. | 10-20-2011 |
| 20110256555 | USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1. | 10-20-2011 |
| 20110251162 | METHODS OF TREATMENT FOR MRSA INFECTIONS - The present subject matter relates to pathogenesis of MRSA. Specifically, the present disclosures identifies the pro-inflammatory properties of PVL as the cause of MRSA. Viewed from this new perspective, the present subject matter achieves novel methods and apparatus for treating MRSA infection in a subject involving the administration of an anti-inflammatory drug to the subject. Furthermore the present subject matter teaches methods and apparatus for treating a Panton-Valetine leukocidin associated infection in a subject involving the administration of an anti-inflammatory drug to the subject. | 10-13-2011 |
| 20110229471 | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD. | 09-22-2011 |
| 20110212048 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM - A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms. | 09-01-2011 |
| 20110189685 | METHODS OF USING JAK3 GENETIC VARIANTS TO DIAGNOSE AND PREDICT CROHN'S DISEASE - The present invention relates to methods of diagnosing and diagnosing susceptibility to Crohn's Disease by determining the presence or absence of risk variants at the JAK3 locus. In one embodiment, the present invention provides a method of diagnosing susceptibility to Crohn's Disease by determining the presence of a risk variant at the JAK3 locus, where the risk variant is associated with positive expression of ASCA and/or anti-I2. | 08-04-2011 |
| 20110177969 | THE ROLE OF IL17RD AND THE IL23-1L17 PATHWAY IN CROHN'S DISEASE - The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease. | 07-21-2011 |
| 20110177487 | METHODS AND APPARATUS FOR PERFUSION OF AN EXPLANTED DONOR HEART - Described herein are methods and apparatus that may be used in various applications, such as to extend the viability of a donor heart, promote the efficacy for transportation of a donor heart, and/or reduce costs associated with donor heart transport and preservation. In one embodiment, the subject matter discloses an effective method and apparatus for comprehensive cold perfusion of an explanted donor heart for improved preservation. | 07-21-2011 |
| 20110171232 | METHODS OF TREATING AUTOIMMUNE DISEASES CAUSED BY SMALL INTESTINAL BACTERIAL OVERGROWTH - Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases. | 07-14-2011 |
| 20110166223 | METHODS OF INHIBITING FGFR3 SIGNALING - Novel inhibitors of FGFR3 signaling having a structure shown as Formula 1 and a method of inhibiting FGFR3 signaling by administering a quantity of the inhibitor, or pharmaceutical equivalent, analog and/or salt thereof, to a mammal are disclosed. Additionally, the inhibitor may be used for treating one or more conditions associated with FGFR3 mediated signaling | 07-07-2011 |
| 20110160765 | METHODS AND DEVICES FOR TREATMENT OF FISTULAS - This invention relates to methods and devices utilizing minimally invasive techniques for digestive system fistula closure using occluder devices and various securing and sealing means. The present subject matter expands upon the breadth of current endoscopic techniques by implementing novel occluder devices and techniques intended specifically for treatment of digestive fistulas. | 06-30-2011 |
| 20110159523 | N-TERMINAL SPECIFIC CHEMICAL LABELING FOR PROTEOMICS APPLICATIONS - Described herein is a method that may be used in various applications, such as drug development, medical diognosis and gene/protein therapy. In one embodiment, the subject matter discloses an effective method for identification and quantification of large sets of proteins/peptides in vitro and cells in vivo. | 06-30-2011 |
| 20110124644 | METHODS OF DIAGNOSING AND CHARACTERIZING CANNABINOID SIGNALING IN CROHN'S DISEASE - Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, 12 and/or anti-Cbir1 antibodies are included | 05-26-2011 |
| 20110117552 | METHODS OF USING A NOD2/CARD15 HAPLOTYPE TO DIAGNOSE CROHN'S DISEASE - The present invention provides a method of diagnosing or predicting susceptibility to Crohn's disease in an individual by determining the presence or absence in the individual of a disease-predisposing haplotype containing a JW1 variant allele at the NOD2/CARD15 locus, where the presence of the disease-predisposing haplotype is diagnostic of or predictive of susceptibility to Crohn's disease. | 05-19-2011 |
| 20110111418 | USE OF IRON-RELATED PATHWAYS AND GENES FOR TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE - A collection of genetic variants having susceptability to, or protection from, Parkinson's Disease is provided. The variants are useful in method of diagnosing, prognosing, and treating Parkinson's Disease and related conditions | 05-12-2011 |
| 20110104210 | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS - Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate. | 05-05-2011 |
| 20110104175 | METHODS OF TREATMENT FOR PULMONARY FIBROSIS - The invention relates to compositions and methods for treating fibrosing lung diseases, reducing pulmonary cytokine production in animals, treating bleomycin induced lung disease and treating cancer. Specifically, the present subject matter incorporates inactivation of the N-terminal site of an angiotensin-converting enzyme and/or administration of AcSDKP. | 05-05-2011 |
| 20110098672 | BALLOON CATHETER AND METHODS FOR PERICARDIOCENTESIS AND PERCUTANEOUS PERICARDIOTOMY - The present subject matter describes a balloon catheter and methods of using the balloon catheter. The balloon catheter is particularly useful for pericardiocentesis and percutaneous pericardiotomy. | 04-28-2011 |
| 20110092435 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 04-21-2011 |
| 20110086804 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 04-14-2011 |
| 20110086073 | NANOMETER-SIZED PRODRUGS OF NSAIDs - The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions. | 04-14-2011 |
| 20110085974 | SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY - The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue. | 04-14-2011 |
| 20110020371 | POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer. | 01-27-2011 |
| 20110014200 | MONOCLONAL ANTIBODY THAT SUPPRESSES THYROTROPIN RECEPTOR CONSTITUTIVE ACTIVITY - This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancer | 01-20-2011 |
| 20110009473 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT - The present invention relates to the use of pituitary tumor transforming gene 1 (PTTG1) as a biomarker for diagnosing cancer as well as for determining cancer treatment responsiveness. In one embodiment, the present invention provides a method of treating cancer by inhibiting the expression of PTTG1, and administering a therapeutically effective amount of Aurora kinase inhibitor, HDAC inhibitor and/or ROS-generating agent. | 01-13-2011 |
| 20110008303 | METHODS FOR TREATMENT AND PREVENTION OF MRSA/MSSA - Described herein are methods for treating and preventing MRSA/MSSA. The present subject matter deviates from current treatment methods by introducing a controlled decolonization/recolonization method, which eradicates the host surface area of MRSA/MSSA, and colonizes the newly cleared surface area with a nonpathogenic or pathogenic bacteria capable of out-competing MRSA/MSSA. | 01-13-2011 |
| 20100331273 | SELF-ASSEMBLING COMPLEX FOR TARGETING CHEMICAL AGENTS TO CELLS - The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs. | 12-30-2010 |
| 20100297152 | METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER - Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer. | 11-25-2010 |
| 20100292174 | CASPASE INHIBITORS IN THE TREATMENT OF INFECTION-ASSOCIATED PRETERM DELIVERY - Apoptotic processes induced by infection of, or injury to, fetal and placental tissues have been implicated in preterm delivery. Thus, modulation of apoptotis constitutes a strategy for improving pregnancy outcome in women with intrauterine infections. Caspase inhibitors, including the pancaspase inhibitor Z-VAD-FMK, can be used to prevent apoptosis and, thus, prevent preterm delivery. Accordingly, compositions and methods comprising caspase inhibitors for prevention of preterm delivery are provided. | 11-18-2010 |
| 20100291222 | ANTIOXIDANT NANOSPHERE COMPRISING [1,2]-DITHIOLANE MOIETIES - The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are also described. Another aspect of this invention is the use of these antioxidant nanospheres for the preparation of antioxidant particulate delivery system of therapeutic agents. | 11-18-2010 |
| 20100284999 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 11-11-2010 |
| 20100280497 | TRANSCECAL ILEOSTOMY SET - Described herein is a transcecal ileostomy set including a balloon catheter equipped with a blocking balloon, which serves for obstruction of a small intestine, and a fixation balloon, which serves for fixation of the balloon catheter inside the large intestine when inflated. Furthermore, it includes a holder, adapted to be fixed to a patient's body from the outside, which serves for closing a large intestine wall by tightening a bioresorbable loop passing through the large intestine wall and abdominal wall. A rotary part of the plastic holder may be affixed with a protrusion serving as a block when turning to tighten the bioresorbable loop. | 11-04-2010 |
| 20100268289 | METHOD AND SYSTEM FOR THE PREDICTION OF CARDIAC ARRHYTHMIAS, MYOCARDIAL ISCHEMIA, AND OTHER DISEASED CONDITION OF THE HEART ASSOCIATED WITH ELEVATED SYMPATHETIC NEURAL DISCHARGES - Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges. | 10-21-2010 |
| 20100240077 | METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2 SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti- | 09-23-2010 |
| 20100240043 | METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus. | 09-23-2010 |
| 20100209507 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 08-19-2010 |
| 20100190162 | METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A. | 07-29-2010 |
| 20100184050 | DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE IN THE PUERTO RICAN POPULATION - This invention provides methods of diagnosis and treatment of inflammatory bowel disease. In one embodiment, the invention provides methods of diagnosing and/or predicting susceptibility for inflammatory bowel disease in the Puerto Rican population by determining the presence or absence of a risk variant at the HPS1 locus. In another embodiment, the invention further provides methods of diagnosing and/or predicting protection against inflammatory bowel disease by determining the presence or absence of a protective variant at the IRF1 locus. In another embodiment, the presence in an individual of a risk variant at the CARD8 locus is diagnostic of susceptibility to Crohn's Disease in a Puerto Rican individual. In another embodiment, the presence of a risk variant at the TLR-9 locus in an individual is diagnostic of susceptibility to Crohn's Disease. | 07-22-2010 |
| 20100183706 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 07-22-2010 |
| 20100173344 | METHODS FOR ISOLATING AND USING PITUITARY ADENOMA STEM CELLS AND PITUITARY ADENOMA CELLS - The present invention describes pituitary adenoma stem cells, pituitary carcinoma stem cells, a method of obtaining the stem cells, and a method of using the stem cells. Uses of the pituitary stem cells include but are not limited to producing pituitary hormones and identifying drugs to treat pituitary disease conditions or pituitary-related disease conditions. | 07-08-2010 |
| 20100170517 | CLOSED SUCTIONING AND RINSING METHODS AND TRACHEAL DEVICES - Described herein is a method and apparatus that may be used in various applications, such as medical treatment of humans and animals. In one embodiment, the subject matter discloses a method for evacuation of secretions in the tracheal tube of a patient during endotracheal intubation by incorporating the use of a novel closed suction tracheal device containing a dedicated primary liquid reservoir, and a volume liquid chamber for supplying the liquid for lavage. | 07-08-2010 |
| 20100144903 | METHODS OF DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus. | 06-10-2010 |
| 20100143304 | ADENOVIRAL VECTOR COMPRISING HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE AND A TRANSGENE FOR INCREASING THE EXPRESSION OF THE TRANSGENE - Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven β-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. β-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression. | 06-10-2010 |
| 20100137212 | USE OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders. | 06-03-2010 |
| 20100130871 | SPECTRAL IMAGING DEVICE FOR HIRSCHSPRUNG'S DISEASE - The subject matter disclosed herein relates to the field of spectral imaging in the diagnosis and treatment of Hirschsprung's disease. Devices and methods are provided that enhance and accurately diagnose Hirschsprung's disease intraoperatively using spectral imaging technology. | 05-27-2010 |
| 20100130600 | LIPOPROTEIN LIPASE AND ITS EFFECT ON STATIN TREATMENTS - The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus. | 05-27-2010 |
| 20100130423 | TREATMENT OF MYELOPROLIFERATIVE DISORDERS WITH ADAPTOR PROTEIN LNK - Janus kinase 2 (JAK2) associates with cytokine receptors and is essential for signal transduction in hematopoietic cells. The JAK2 mutation, JAK2 V617F, prevalent in myeloproliferative disorders, confers cytokine-independent proliferation and constitutive activation of downstream signaling pathways, when co-expressed with homodimeric type I cytokine receptors. The adaptor protein LnK is a negative regulator of hematopoietic cytokine receptors, including EPOR and MPL. LnK attenuates wild type JAK2 signaling in hematopoietic Ba/F3 cells expressing MPL. LnK also inhibits cytokine-independent growth and signaling conferred by JAK2 V617F in those cells. LnK, via its SH2 domain, PH domain, and other regions, associates with JAK2 and JAK2 V617F. Additional LnK domains are involved in LnK downregulation of JAK2 V617F constitutive activation. Elucidating the pathways that attenuate JAK2 and JAK2 V617F signaling provides insight into myeloproliferative disorders and helps to develop therapeutic approaches. Inhibition of Lnk enhances the expression of hematopoetic stem cells and hematopoetic progenitor cells. | 05-27-2010 |
| 20100105044 | ILEAL POUCH-ANAL ANASTOMOSIS (IPAA) FACTORS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - A common long term problem after Ileal Pouch-Anal Anastomosis (IPAA) is the inflammation of the pouch, called pouchitis. Additionally, about 5-10% of patients undergoing IPAA with a diagnosis of ulcerative colitis at the time of surgery are subsequently diagnosed with Crohn's disease. In one embodiment, the present invention provides methods of diagnosing and predicting susceptibility to pouchitis after IPAA by detecting the presence or absence of pANCA and/or Cbir1 Flagellin expression. | 04-29-2010 |
| 20100098653 | ANTIOXIDANT POLYMERS CONTAINING [1,2]-DITHIOLANE MOIETIES AND USES THEREOF - The present invention describes polymers containing 1,2-dithiolanes capable of acting as scavengers of free radicals, metals and reactive oxygen species. Also described are methods of synthesizing the antioxidant 1,2-dithiolane derivatives and polymerization thereof to produce biodegradable antioxidant polymers. The antioxidant polymers of the present invention may be used to treat diseases or conditions caused by oxidative stress and other free radical mediated conditions. The antioxidant polymers may also be used for the preparation of antioxidant particulate delivery devices of therapeutic agents. | 04-22-2010 |
| 20100087406 | INDUCTION OF INNATE IMMUNITY BY VITAMIN D3 AND ITS ANALOGS - Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D | 04-08-2010 |
| 20100068303 | TREATMENT OF CANCER WITH BIO AND CHEMOTHERAPY - This invention relates to compositions and methods utilizing a chemotherapeutic drug and 6-bromoindirubin3′-oxime (BIO) for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that BIO works synergistically with chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells. | 03-18-2010 |
| 20100063423 | ULTRASONIC BATH TO INCREASE TISSUE PERFUSION - The present invention describes a method of using an ultrasonic bath to enhance tissue perfusion, enhance the development of collateral blood vessels and/or enhance collateral circulation in an extremity in need thereof. Also described is an ultrasonic bath adapted to hold media and to permit the immersion of an extremity and comprising one or more ultrasonic transducers to generate and transmit ultrasonic energy to the extremity or the inventive method | 03-11-2010 |
| 20100062477 | METHODS OF ISOLATING AND PROPAGATING STEM CELLS FROM BENIGN TUMORS - The present invention describes benign tumor stem cells, a method of isolating the benign tumor stem cells, a method of generating the benign tumor stem cells and a method of using the benign tumor stem cells. Uses of the benign tumor stem cells, such as pituitary stem cells include but are not limited to producing pituitary hormones and identifying drugs to treat pituitary disease conditions or pituitary-related disease conditions. | 03-11-2010 |
| 20100061980 | ASSAYS TO PREDICT AND MONITOR ANTIBODY MEDIATED REJECTION OF TRANSPLANTED ALLOGRAFTS - The present invention is directed to assays that may be used to measure B cell reactivity to allo or donor antigens in patients, gauge the efficacy of desensitization treatment of these individuals, predict antibody mediated rejection, and monitor patients post transplant for antibody mediated rejection. | 03-11-2010 |
| 20100055700 | ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors. | 03-04-2010 |
| 20100055697 | POSITIVE SELECTION OF SERUM PROTEINS FOR PROTEOMIC ANALYSIS - This invention relates to methods and kits for positive selection of species of interest based on peptide/protein sequence from a biological sample. The species of interest may be proteins and/or peptides of interest which may be placed through a mass spectrometer to obtain a blood peptide/protein signature. The blood peptide/protein signature may be used in proteomic analysis. The techniques include but are not limited to the use of collectors comprising nucleic acid molecules to extract a composition that has a lower concentration of a high abundance species of interest from a sample. This limits the level of influence that any collectors species may have on the results of a mass spectra. | 03-04-2010 |
| 20100040585 | METHODS FOR ISOLATING AND USING HEMATOPOIETIC AND EMBRYONIC STEM CELLS OF THE PERITONEAL CAVITY - The invention relates to the isolation and use of hematopoietic and embryonic stem cells. Additionally, the inventors identified the peritoneal cavity as a new source of hematopoietic stem cells. In one embodiment, the invention provides methods of isolating progenitor and/or stem cells from the peritoneal cavity. In another embodiment, the invention provides methods of transporting progenitor and/or stem cells from the peritoneal cavity to another organ. In another embodiment, the present invention provides methods of regenerating bioengineered tissues and/or reconstituting an hematopoietic system. | 02-18-2010 |
| 20100021917 | METHODS OF USING GENES AND GENETIC VARIANTS TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility to inflammatory bowel disease by determining the presence or absence of genetic variants. In one embodiment, a the invention is practiced by determining the presence or absence of NOD2 variants in an individual where the presence of NOD2 variants are indicative of susceptibility to Crohn's Disease in the individual. In another embodiment, the invention further determines the presence or absence of TLR8 variants where the presence of TLR8 variants are inflammatory bowel disease in female individuals. In another embodiment, the invention further determines the presence or absence of TR2 variant P631H where the presence of TLR2 variant P631H is indicative of susceptibility to Crohn's Disease. | 01-28-2010 |
| 20100021455 | METHODS FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and/or small intestine. | 01-28-2010 |
| 20100016684 | ELECTRONIC DEVICE AND SYSTEM FOR DETECTING REJECTION IN TRANSPLANT RECIPIENTS - The current invention relates to an implantable device, system, method, and computer readable medium comprising computer executable components for detection of rejection of a cardiac allograft. Acute rejection and chronic rejection are the leading cause of death in heart transplant recipients post transplant. The current invention seeks to address this problem by providing methods, devices, systems and computer readable media comprising computer executable components to monitor the efficacy of immunosuppressant therapy and evaluate the degree of rejection in a cardiac allograft. To provide this functionality, an implantable device comprises sensors which measure physiologic parameters at specified intervals after the transplant procedure. These measured parameters are subsequently compared with baseline parameter data to detect rejection of the cardiac allograft. | 01-21-2010 |
| 20100015156 | DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN CHILDREN - This invention provides methods of diagnosing and predicting disease progression of Crohn's disease. In one embodiment, a method of the invention is practiced by determining the presence or absence of CARD15 variants R702W, G908R, and/or 1007insC in a pediatric individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, and/or pANCA in a pediatric individual | 01-21-2010 |
| 20100011997 | DOCKABLE COMPUTER STATION - The invention relates to a mobile cart adapted to engage with an item of stationary furniture and/or to other mobile carts. In one embodiment, the mobile cart contains one or more units configured to interact when the mobile cart and stationary item of furniture are secured to one another. In another embodiment, the mobile cart is a work station adapted to be moved among different locations. | 01-21-2010 |
| 20100004430 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 01-07-2010 |
| 20090325994 | METHODS OF TREATING DIARRHEA CAUSED BY SMALL INTESTINAL BACTERIAL OVERGROWTH - Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease. | 12-31-2009 |
| 20090317367 | METHODS OF PRODUCING PREADIPOCYTES AND INCREASING THE PROLIFERATION OF ADULT ADIPOSE STEM/PROGENITOR CELLS - The present invention describes preadipocytes and methods of differentiating macrophages into preadipocytes by co-culturing adipocytes and resident adipose tissue macrophages. Also described are methods of increasing the proliferative rate of adipose adult stem/progenitor cells. | 12-24-2009 |
| 20090286243 | Compositions and methods for spinocerebellar ataxia - Mutations in the KCNC3 (Kv3.3) voltage-gated potassium channel gene result in spinocerebellar ataxia. | 11-19-2009 |
| 20090280126 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 11-12-2009 |
| 20090278037 | ESTIMATION OF ION CYCLOTRON RESONANCE PARAMETERS IN FOURIER TRANSFORM MASS SPECTROMETRY - The present invention comprises a method and system for accurate estimation of the ion cyclotron resonance (ICR) parameters in Fourier-transform mass spectrometry (FTMS/FT-ICR MS). The parameters are essential to estimating the mass to charge ratio of an ion from FT-ICR MS data, the intended purpose of the instrument. Achieving greater accuracy in the parameters assists in greater accuracy of the mass to charge ratio of an ion, and obtaining an accurate estimation of the mass to charge ratio of an ion further aides in detecting mass with sub-ppm accuracy. Estimating mass in this manner enhances identification and characterization of large molecules. The inventive method and system thereby enhances the data obtained by conventional FTMS by accurately estimating ICR parameters. Ultimately, accurate estimates of the masses of molecules and detection and characterization of molecules from FT-ICR MS data are obtained. | 11-12-2009 |
| 20090264483 | METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER - This invention relates to compositions and methods utilizing a caspase-dependent chemotherapeutic drug and a PPARy-agonist, such as VP-16 or Taxol as the chemotherapeutic drug and troglitazone or pioglitazone as the PPARy agonist, for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that PPAR agonists work with caspase-dependent chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells. | 10-22-2009 |
| 20090263379 | MONOCLONAL ANTIBODIES FOR INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS - Using gene array technology, we observed that an increase of the alpha-4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we confirmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both alpha-4 and β1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells. | 10-22-2009 |
| 20090253133 | ENHANCED T CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE - A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed. | 10-08-2009 |
| 20090232735 | USE OF FRUCTOSE-BASED THERAPIES FOR THE TREATMENT OF CANCER - The methods and compositions of the invention are based on the preferential utilization of fructose by cancer cells. This invention relates to compositions, methods and kits utilizing fructose and other monosaccharides for the treatment of cancer. This invention also relates to methods and kits for using compositions to mimic or corrupt metabolic pathways of fructose and/or signal transduction pathways related to cancer cells for the treatment of cancer. | 09-17-2009 |
| 20090221007 | DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease. | 09-03-2009 |
| 20090203991 | MULTIPLE IMAGING AND/OR SPECTROSCOPIC MODALITY PROBE - The apparatus and methods described herein enable an operator to simultaneously collect images and spectroscopic information from a region(s) of interest using a multiple modality imaging and/or spectroscopic probe, configured as a catheter, endoscope, microscope, or hand held probe. The device may incorporate, for example, an ultrasonic transducer and a fiber optic probe to translate images and spectra. The apparatus and methods may be used in any suitable cavity, for example, the vascular system of a mammal. | 08-13-2009 |
| 20090202555 | ANTIBODIES AGAINST A PEPTIDE EPITOPE OF APOLIPOROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 08-13-2009 |
| 20090202523 | ANTIBODIES AGAINST A PEPTIDE EPITOPE OF APOLIPOROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 08-13-2009 |
| 20090175787 | USE OF FRUCTOSE-BASED COMPOUNDS FOR THE DIAGNOSIS OF CANCER - This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of these features and provides for fructose or fructose-based compositions for the diagnosis of cancer using imaging techniques such as positron emission tomography. | 07-09-2009 |
| 20090142741 | MEDICAL TRAINING METHODS AND DEVICES - The present subject matter relates to medical training methods and models. In one embodiment, the invention provides for devices and methods of training paracentesis procedures. In another embodiment, the subject matter provides for devices and methods of training thoracentesis procedures. In yet another embodiment, the present subject matter provides for a training methods and model for performing lumbar punctures. | 06-04-2009 |
| 20090117178 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 05-07-2009 |
| 20090117137 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 05-07-2009 |
| 20090053740 | AGGLUTINATION-BASED METHOD FOR FAST DETECTION, ISOLATION AND QUANTIFICATION OF APOPTOTIC CELLS - The present invention relates to methods and kits for the detection, isolation and quantification of apoptotic cells based on the apoptotic cells' increased expression of alpha-D-mannose and/or beta-D-galactose containing glycoproteins. Lectins that bind to alpha-D-mannose and beta-D-galactose-rich glycoconjugates are used in the methods and kits for agglutination tests for the detection, isolation and quantification of apoptotic cells. Lectins may be used to stimulate the agglutination of cells and apoptosis may be detected by assessing the concentration of lectins required to agglutinate a cell population and comparing the concentration to predetermined values for intact cells and cells in various stages after induction of apoptosis. | 02-26-2009 |
| 20090048179 | USE OF 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER OF ABNORMAL BRAIN TISSUE AND THE BLOOD-TUMOR BARRIER - This invention relates to methods and kits for enhancing the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier. Particularly, methods comprising the administration of 5-phosphodiesterase inhibitors, such as sildenafil and vardenafil, to selectively enhance the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier are described. This selective enhancement allows for selective delivery of therapeutic agents or imaging to treat the abnormal brain tissue or a tumor, including brain tumors and non-central nervous system tumors. | 02-19-2009 |
| 20090012113 | METHODS OF TREATING A SUBJECT SUFFERING FROM IRRITABLE BOWEL SYNDROME - Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome. | 01-08-2009 |
| 20090008546 | Bi-Directional System For Mass Spectrometry - The present invention relates to a system and method for mass spectrometry ( | 01-08-2009 |
| 20080317837 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 12-25-2008 |
| 20080312614 | TRANSCECAL ILEOSTOMY SET - Described herein is a transcecal ileostomy set including a balloon catheter equipped with a blocking balloon, which serves for obstruction of a small intestine, and a fixation balloon, which serves for fixation of the balloon catheter inside the large intestine when inflated. Furthermore, it includes a holder, adapted to be fixed to a patient's body from the outside, which serves for closing a large intestine wall by tightening a bioresorbable loop passing through the large intestine wall and abdominal wall. A rotary part of the plastic holder may be affixed with a protrusion serving as a block when turning to tighten the bioresorbable loop. | 12-18-2008 |
| 20080293585 | 5'/3' Ratioing Procedure for Detection of Gene Rearrangements - The present invention relates to methods and kits useful for the detection of gene rearrangements and the diagnosis of a propensity to develop a disease condition caused by the gene rearrangements, wherein two PCR products are prepared from the 5′ side and from the 3′ side of a putative breakpoint of the gene of interest, and the ratio of the two products are measured. | 11-27-2008 |
| 20080286745 | Methods and Solutions for Tissue Preservation - Described herein are compositions and methods particularly useful in the medical arts. The compositions and methods may be used in connection with the preservation of a portion of a mammal, for example, tissues, organs, appendages, limbs, extremities, stem cells, myocytes, bone marrow, skeletal muscle as well as an array of other medical procedures, such as cardiac surgery, transplantation and/or preservation. In various embodiments, the inventive composition may be hyperoxygenated and be formulated to resemble the biochemistries of natural intracellular fluids. The inventive composition includes active ingredients to reduce ischemic, hypothermic and reperfusion injury during transplantation, thereby resulting in improved post-transplant graft function and quality, when used in connection with organ transplantation and storage procedures, for example cardiac transplantation. | 11-20-2008 |
| 20080286285 | Methods for Treating Vascular Disease - Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88). TLR4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway by affecting the biological activity of the TLR4 receptor and/or MyD88. | 11-20-2008 |
| 20080274170 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 11-06-2008 |
| 20080274086 | Use of Cxcr4 Protein Expression on the Surface of Stem Cells as a Marker for Tumor Tropic Potential - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1. | 11-06-2008 |
| 20080268478 | Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation - The invention disclosed herein relates to the detection or diagnosis of atherosclerosis by measuring the level of the protein eotaxin in an individual's serum. The presence of eotaxin above levels specified herein is indicative that atherosclerosis may be present. Detection of elevated eotaxin levels in serum may provide a means to diagnose atherosclerosis prior to the onset of symptoms. | 10-30-2008 |
| 20080268029 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 10-30-2008 |
| 20080253641 | Method for Drug Screening and Characterization by Calcium Flux - The instrumentation and methods described herein are based on imaging and measuring single cell dose response by fluorescent ion imaging that records live cell responses to drug doses with no apparent damage to the cells or toxic side effects. Dose response curves and other pharmacological parameters can be computed by imaging and measuring oscillation changes for each dose and each cell. Large variability of cellular responses under the same experimental conditions indicates that pharmacological benchmarks are determined by statistical distribution of cells and cellular physiology. The instrumentation and methods described herein provide a means of measuring statistical variability of cell populations for improved screening and development methods for drugs. | 10-16-2008 |
| 20080207657 | Use Of Minoxidil Sulfate As An Anti-Tumor Drug - The invention relates to compositions, methods and kits for the treatment of cancer. ATP-dependent potassium channel agonists, salts thereof, or chemical analogs thereof, for example, minoxidil sulfate, have been found to possess anti-neoplastic properties. Administering minoxidil sulfate may prolong the life of a cancer patient; for example, a patient with a brain tumor. | 08-28-2008 |
| 20080203284 | Method For Simultaneous Calibration of Mass Spectra and Identification of Peptides in Proteomic Analysis - The invention relates to a mass spectrometry calibration system that may be performed in real-time using the information contained within a sample without the addition of specific calibrants. When applied to a sample, such as a proteomic sample, the calibration system may identify the exact masses of peptides in the sample. The system involves the use of mathematical algorithms that iteratively estimate the error in the measurement and update the calibration parameters accordingly; thereby resulting in peptide mass identification. | 08-28-2008 |
| 20080199931 | POLYNUCLEOTIDE ENCODING AN INTRACELLULAR ESTRADIOL BINDING PROTEIN - Described herein is a novel intracellular estradiol binding protein (“IEBP”), as well as a polynucleotide encoding this protein and various cells and cell lines producing and/or overexpressing it. IEBP is believed to play a role in the modulation of estrogen signaling and in the physiological resistance to the same. Abnormally elevated or decreased levels of IEBP may thus be a component of the etiology of diseases generally correlated with estrogen signaling, such as, by way of example, breast cancer and osteoporosis. Various embodiments of the present invention are believed to provide important tools for developing treatments for these conditions, such as, for example, by providing means for screening therapeutic compounds and identifying a genetic target for therapy. | 08-21-2008 |
| 20080199484 | Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy - The present invention relates to a method and combination therapy useful in the treatment of cancer. More specifically, the invention relates to the use of COX-2 inhibitors in combination with a therapeutic dendritic cell vaccine for treating cancer. The COX-2 inhibitors of the present invention are believed to inhibit the enzymatic activity of prostaglandineE | 08-21-2008 |
